FDA says Infinant Health's Evivo with MCT Oil probiotic is an unapproved biologic drug and unsafe food additive for preterm infants.
What happened
FDA reviewed Infinant Health's website and marketing materials, including an Evivo with MCT Oil product information sheet, in September 2023. FDA found the product promoted for infants and specifically for preterm infants in the neonatal intensive care unit (NICU), with references to articles about reducing necrotizing enterocolitis. FDA concluded the product is an unapproved new drug and unlicensed biological product and, for preterm infants, an adulterated food containing an unsafe food additive.
What FDA found
The product is a drug because Infinant's website and materials say it is intended to prevent or treat disease, including necrotizing enterocolitis, but it has no approved biologics license application (BLA).
21 U.S.C. § 321(g)(1)(B); 42 U.S.C. § 262(a)The product is a biological product that requires a valid license, and FDA says no BLA or investigational new drug application is in effect for it.
42 U.S.C. § 262(a); 21 U.S.C. § 355(i); 21 CFR Part 312For use in food for preterm infants, B. longum subsp. infantis EVC001 is an unsafe food additive because there is no food additive approval and FDA says it is not generally recognized as safe (GRAS) for that use.
21 U.S.C. § 342(a)(2)(C)(i); 21 U.S.C. §§ 321(s), 348(a)The product was introduced or delivered for introduction into interstate commerce even though it was an unapproved new drug and unlicensed biological product, which is prohibited.
21 U.S.C. § 331(d); 42 U.S.C. § 262(a)(1)The product was introduced or delivered for introduction into interstate commerce as an adulterated food—meaning it contains an unsafe food additive—which is prohibited.
21 U.S.C. § 331(a)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the specific steps taken to correct the violations, with an explanation of each step and documentation to prevent recurrence. If all corrections cannot be completed in that time, FDA asks for the reason and the date by which they will be completed.
Who should pay attention
- probiotic companies marketing to infants or preterm infants
- NICUs and healthcare providers that buy or use probiotic products
- infant formula and food ingredient suppliers that rely on GRAS status
This is a summary. Read the original letter on fda.gov.